Alnylam Pharmaceuticals | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Arrowhead Research USD 30.2M 1.91M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Sanofi EUR 1.24B 1.44B 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Takeda JPY 270.59B 2.31B 2024-12
Tectonic Therapeutic USD 4.84M 469K 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12
Xencor USD 14.92M 148K 2024-12



Alnylam Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.